These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 2024665)

  • 21. [The importance of erythropoietin in the therapy of anemia in patients on chronic hemodialysis].
    von Appen K; Klinkmann H
    Urol Nefrol (Mosk); 1990; (6):69-70. PubMed ID: 2089771
    [No Abstract]   [Full Text] [Related]  

  • 22. [Erythropoietin--the first hematologic hormone in clinical use].
    Rhyner K
    Schweiz Med Wochenschr; 1988 Mar; 118(11):375-80. PubMed ID: 3287601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A hematocrit greater than 36 lessens mortality and hospitalization in hemodialysis].
    Fernández-Gallego J; Gutiérrez C
    Nefrologia; 2003; 23(2):177-8. PubMed ID: 12778885
    [No Abstract]   [Full Text] [Related]  

  • 24. Erythropoietin.
    Beresford CH
    N Z Med J; 1989 Apr; 102(866):185-6. PubMed ID: 2652007
    [No Abstract]   [Full Text] [Related]  

  • 25. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US Recombinant Human Erythropoietin Predialysis Study Group.
    Am J Kidney Dis; 1991 Jul; 18(1):50-9. PubMed ID: 2063855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early intervention with recombinant human erythropoietin therapy.
    Teehan BP; Benz RL; Sigler MH; Brown JM
    Semin Nephrol; 1990 Mar; 10(2 Suppl 1):28-34. PubMed ID: 2192414
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost of treating predialysis patients with recombinant human erythropoietin.
    Durand-Zaleski I; Goldfarb B; Blum-Boisgard C; Drüeke T; Kreis H
    Nephrol Dial Transplant; 1993; 8(4):311-4. PubMed ID: 8390004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Should the hematocrit (hemoglobin) be normalized in Pre-ESRD or dialysis patients? Yes!
    Besarab A; Aslam M
    Blood Purif; 2001; 19(2):168-74. PubMed ID: 11150804
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment of anemia in chronically dialyzed patients].
    Moynot A
    Nephrologie; 1998; 19(3):125-7. PubMed ID: 9633055
    [No Abstract]   [Full Text] [Related]  

  • 30. Management of blood pressure changes during recombinant human erythropoietin therapy.
    Levin N
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):16-20. PubMed ID: 2669081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Erythropoietin: from established therapeutic procedures in renal anemia to future areas of use].
    Marsen TA; Pollok M; Baldamus CA
    Med Klin (Munich); 1992 Apr; 87(4):207-14. PubMed ID: 1579099
    [No Abstract]   [Full Text] [Related]  

  • 32. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
    Binkley LS
    Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
    Frenken LA; Verberckmoes R; Michielsen P; Koene RA
    Nephrol Dial Transplant; 1989; 4(9):782-6. PubMed ID: 2516609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of blood rheology in the pathogenesis of hypertension of hemodialysis patients treated for renal anemia with recombinant human erythropoietin.
    Baldamus CA; Steffen AM; Brunner R; Pollok M
    Contrib Nephrol; 1990; 82():79-85. PubMed ID: 2093531
    [No Abstract]   [Full Text] [Related]  

  • 35. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Favourable effects of the treatment of renal anemia in early stage chronic renal failure].
    Kes P
    Lijec Vjesn; 2002; 124(3-4):108-9. PubMed ID: 18956830
    [No Abstract]   [Full Text] [Related]  

  • 37. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
    Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensity of hemodialysis and response to erythropoietin.
    Uréna P; Pétrover M
    N Engl J Med; 1996 Jun; 334(25):1669; author reply 1670-1. PubMed ID: 8628368
    [No Abstract]   [Full Text] [Related]  

  • 39. Utilization of erythropoietin in the treatment of the anemia due to chronic renal failure.
    Drüeke T; Zins B; Naret C; Casadevall N; Goureau Y; Bererhi L; Peterlongo F; Castaigne JP; Zingraff J; Delons S
    Adv Nephrol Necker Hosp; 1989; 18():187-206. PubMed ID: 2493715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
    Mohini R
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.